Xencor, Inc. (NASDAQ:XNCR – Get Free Report) has earned an average rating of “Hold” from the nine research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $24.8571.
XNCR has been the subject of a number of analyst reports. Cantor Fitzgerald raised their price objective on Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Royal Bank Of Canada lifted their target price on Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Wedbush boosted their price target on Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a report on Wednesday, June 24th. Finally, Truist Financial dropped their price objective on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th.
Check Out Our Latest Stock Analysis on Xencor
Xencor Price Performance
Xencor (NASDAQ:XNCR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The business had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. During the same quarter in the prior year, the company earned ($0.41) earnings per share. The business’s revenue was up 17.4% compared to the same quarter last year. Research analysts expect that Xencor will post -3 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Xencor
Hedge funds have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. grew its stake in shares of Xencor by 620.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after purchasing an additional 620,440 shares during the period. Vanguard Group Inc. lifted its stake in shares of Xencor by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after purchasing an additional 61,692 shares during the period. Erste Asset Management GmbH grew its position in Xencor by 26.3% during the fourth quarter. Erste Asset Management GmbH now owns 480,200 shares of the biopharmaceutical company’s stock valued at $7,347,000 after buying an additional 100,000 shares during the period. Dimensional Fund Advisors LP raised its position in Xencor by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock worth $15,613,000 after acquiring an additional 45,599 shares during the period. Finally, BVF Inc. IL raised its position in Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after acquiring an additional 4,393,579 shares during the period.
About Xencor
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.
See Also
- Five stocks we like better than Xencor
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
